{"nctId":"NCT03601637","briefTitle":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del","startDateStruct":{"date":"2018-09-07","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":61,"armGroups":[{"label":"Part A: LUM/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: LUM","Drug: IVA"]},{"label":"Part B: LUM/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: LUM","Drug: IVA"]}],"interventions":[{"name":"LUM","otherNames":["lumacaftor","VX-809"]},{"name":"IVA","otherNames":["ivacaftor","VX-770"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Participants will be 1 to less than 2 years of age on day 1 of the relevant part of the study\n* Homozygous for F508del (F/F)\n\nKey Exclusion Criteria:\n\n* Any clinically significant laboratory abnormalities at the screening visit that would interfere with the study assessments or pose an undue risk for the participants\n* Solid organ or hematological transplantation\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","maximumAge":"23 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14600","spread":"5560"},{"groupId":"OG001","value":"12600","spread":"7190"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16600","spread":"9590"},{"groupId":"OG001","value":"13900","spread":"5800"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1620","spread":"648"},{"groupId":"OG001","value":"1320","spread":"804"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"718","spread":"352"},{"groupId":"OG001","value":"496","spread":"268"}]}]}]},{"type":"PRIMARY","title":"Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12000","spread":"8880"},{"groupId":"OG001","value":"12800","spread":"3900"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8380","spread":"7790"},{"groupId":"OG001","value":"10500","spread":"3070"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":"75.5"},{"groupId":"OG001","value":"185","spread":"101"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":"19.1"},{"groupId":"OG001","value":"120","spread":"60.5"}]}]}]},{"type":"PRIMARY","title":"Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1410","spread":"791"},{"groupId":"OG001","value":"1470","spread":"365"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1460","spread":"1060"},{"groupId":"OG001","value":"1370","spread":"468"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"606","spread":"298"},{"groupId":"OG001","value":"842","spread":"527"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":"70.2"},{"groupId":"OG001","value":"604","spread":"394"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2380","spread":"843"},{"groupId":"OG001","value":"3290","spread":"1830"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1460","spread":"763"},{"groupId":"OG001","value":"2800","spread":"2300"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Sweat Chloride","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.1","spread":"13.5"}]}]}]},{"type":"SECONDARY","title":"Part B: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13500","spread":null},{"groupId":"OG001","value":"9030","spread":"4390"},{"groupId":"OG002","value":"887","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21900","spread":null},{"groupId":"OG001","value":"9370","spread":"5030"},{"groupId":"OG002","value":"1000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12100","spread":null},{"groupId":"OG001","value":"9160","spread":"4400"},{"groupId":"OG002","value":"566","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11200","spread":null},{"groupId":"OG001","value":"8930","spread":"5310"},{"groupId":"OG002","value":"288","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1460","spread":null},{"groupId":"OG001","value":"1260","spread":"528"},{"groupId":"OG002","value":"786","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1570","spread":null},{"groupId":"OG001","value":"1340","spread":"579"},{"groupId":"OG002","value":"602","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1740","spread":null},{"groupId":"OG001","value":"1440","spread":"599"},{"groupId":"OG002","value":"501","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1870","spread":null},{"groupId":"OG001","value":"1470","spread":"548"},{"groupId":"OG002","value":"569","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"112","spread":"68.3"},{"groupId":"OG002","value":"3.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"267","spread":null},{"groupId":"OG001","value":"112","spread":"82.9"},{"groupId":"OG002","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"286","spread":null},{"groupId":"OG001","value":"91.7","spread":"44.7"},{"groupId":"OG002","value":"2.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","spread":null},{"groupId":"OG001","value":"144","spread":"296"},{"groupId":"OG002","value":"2.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1420","spread":null},{"groupId":"OG001","value":"437","spread":"291"},{"groupId":"OG002","value":"18.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1930","spread":null},{"groupId":"OG001","value":"466","spread":"359"},{"groupId":"OG002","value":"58.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"759","spread":null},{"groupId":"OG001","value":"418","spread":"236"},{"groupId":"OG002","value":"18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"256","spread":null},{"groupId":"OG001","value":"499","spread":"613"},{"groupId":"OG002","value":"18.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4740","spread":null},{"groupId":"OG001","value":"1930","spread":"1460"},{"groupId":"OG002","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9090","spread":null},{"groupId":"OG001","value":"1970","spread":"1490"},{"groupId":"OG002","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3520","spread":null},{"groupId":"OG001","value":"1950","spread":"1430"},{"groupId":"OG002","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1320","spread":null},{"groupId":"OG001","value":"1740","spread":"1130"},{"groupId":"OG002","value":"63.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Cough","Pyrexia","Rhinorrhoea","Vomiting","Infective pulmonary exacerbation of cystic fibrosis"]}}}